| G-U KEEPS UP ITS SEX DRIVE |
EP Vantage October 08, 2008: The potential US approval of UCB’s Toviaz for overactive bladder is unlikely, punning aside, to make as much of a splash when the drug goes up before the FDA in the next couple of months. |
| Deals up, upfront fees down |
EP Vantage: An analysis of deal data from EvaluatePharma reveals that a total of 417 tangible product deals have been signed over the last year, with an aggregate potential deal value of a staggering $40.1bn, with the deals remaining significantly back-ended, as upfront fees represent just 12% of this total. |
| High hopes for almorexant? |
| July 14, 2008 - Actelion was probably hoping for a slightly more effusive reaction to its heavily trailed SFr3.3bn ($3.2bn) deal with GlaxoSmithKline for insomnia drug almorexant announced today, rather than the meagre 4% advance its share price notched up. |
| Merck's shopping list? |
May 2, 2008: When Merck & Co’s chief executive Richard Clark revealed last week that the US pharma giant is “aggressively looking” for a suitable biotech company to buy, it initially sounded like any number of big pharma CEO interviews in recent months, reassuring shareholders that they are striving to bolster thin pipelines and plug patent expiry holes with the “right” acquisition. |
| GI set to stagnate |
February 14, 2008: The spin off by AstraZeneca of certain of its gastro-intestinal projects today stems from the group’s decision a year ago to cease the majority of research into one of the lowest growth therapy areas, and focus its efforts on bigger opportunities. |
| Isis's novel financing route |
January 08, 2008: The key licensing deal Isis Pharmaceuticals announced late yesterday with Genzyme highlights the success of a novel financing route the US biotech pursued to fund early trials of the compound. |
| FDA slows Avastin |
December 6th 2007: The decision by an FDA oncology advisory committee to reject the use of Avastin in metastatic breast cancer is the clearest demonstration yet of the tough line that regulators are taking over approval of cancer drugs. |
| Schering-Plough and Organon |
Updated: December 19th 2007: Schering-Plough completes acquisition of Organon BioSciences. |
| AZ acquires MedImmune |
June 29th 2007: AstraZeneca completed its acquisition of MedImmune for $58 in cash per share on June 18th, for a total consideration of $15.6bn (including approx. $340m net cash). |
| Mylan and Merck Generics |
June 29th 2007: EvaluatePharma subscribers can view analysis of Mylan's proposal to acquire the generics business of Merck KGaA for $6.6bn in cash, thereby establishing itself as the third biggest generic company worldwide. |
| Mitsubishi and Tanabe to Merge |
February 9th 2007: Mitsubishi and Tanabe have announced their intention to merge. |
| Pfizer Drops Torcetrapib |
December 4th 2006: Pfizer announced on December 2nd 2006 that all clinical trials for torcetrapib were to be stopped. |
| Actelion Acquires CoTherix |
November 20th 2006: Actelion announced plans to acquire CoTherix, a pharmaceutical company focused on the development of cardiovascular therapies, for approximately $420m in cash. |
| Abbott to Acquire Kos |
November 6th 2006: Abbott Laboratories announced that it has entered into a definitive agreement to acquire Kos Pharmaceuticals for $3.7bn in cash (net of cash acquired). |
| Genentech to Acquire Tanox |
November 10th 2006: Genentech announced plans to acquire Tanox, a biotechnology company focused on the development of therapeutic monoclonal antibodies, for approximately $920m in cash. |
| 3M to Sell Its Pharma Business |
November 10th 2006: 3M announced agreements to sell its pharmaceuticals business for a total deal value of approximately $2.1bn. |
| Generics consolidation |
October 26th, 2006: Recent acquisitions activity in the generics sector has seen Barr Pharmaceuticals' make a bid valued at $2.5bn to acquire PLIVA and Hospira's proposed $2.0bn acquisition of Mayne Pharma. |
| European M&A Speeds Up |
September 27, 2006 In a busy week for European mid-sized pharma, Merck KGaA announced an agreement to purchase the majority holding in Serono, Nycomed announced an agreement to purchase ALTANA Pharma, and UCB and Schwarz Pharma announced the terms of a deal for UCB to acquire Schwarz. |
| UCB to Acquire Schwarz |
September 25th 2006: UCB and Schwarz Pharma announced they have agreed the terms of a cash and shares offer for UCB to acquire Schwarz Pharma. The proposal comprises €50 in cash and 0.8735 UCB share per Schwarz Pharma share, valuing Schwarz at €91.1 per share, or €4.4bn total equity. |
| Nycomed to Acquire ALTANA Pharma |
September 22nd 2006: Nycomed announced it has entered into an agreement to purchase the entire pharmaceuticals business of Altana (Altana Pharma) for €4.5bn in cash. The supervisory board of Altana has approved this transaction, which is expected to close on January 1, 2007. |
| Merck KGaA to Acquire Serono |
September 21st 2006: Merck KGaA announced it has entered into an agreement to purchase the Bertarelli family's majority stake in Serono for CHF 1,100 per share in cash. Upon closing of this deal, Merck KGaA will hold 64.5% of the capital in Serono and 75.5% of the voting rights. |
| Bayer Takes Over Schering |
Updated July 26th 2006: Bayer completes acquisition of Schering AG. Offer price rises to $89 per share from $86 following the acquisition of a 22% stake in Schering AG by Merck KGaA... |
| AstraZeneca to Acquire CAT |
May 15th 2006: View analysis of AstraZeneca’s proposed acquisition of Cambridge Antibody Technology, a UK biotech company specialising in the development of monoclonal antibodies... |
| Merck KGaA Drops $17.7bn Offer for Schering AG |
March 24th 2006: In response to Bayer's higher offer ($19.5bn) for Schering AG, Merck KGaA will not increase its offer and has decided not to pursue its hostile takeover bid for Schering AG. View analysis of Merck KGaA's original offer |
| Watson to Acquire Andrx for $1.9bn |
March 13th 2006: EvaluatePharma subscribers may view analysis of Watson’s proposed $1.9bn all-cash offer to acquire Andrx |
| Pharmaceutical Majors - Quarterly & Year End 2005 Analysis |
February 8th 2006: EvaluatePharma subscribers may view the latest Q4/FY 2005 product sales & segment data in EvaluatePharma. Now includes: All Global Majors. |
| All Forecasts Extended to 2010! |
December 22nd 2005: EvaluatePharma has extended consensus forecasts to 2010 on all products forecasts, company therapy area sales, portfolio analysis and financial statements. |
